Drug Interaction Report

ADJUST DOSE: Coadministration with danicopan may increase the plasma concentrations and effects of rosuvastatin. The proposed mechanism is decreased clearance of rosuvastatin due to danicopan-mediated inhibition of the efflux transporter breast cancer resistance protein (BCRP). In a clinical drug interaction study, when subjects were coadministered rosuvastatin (single 20 mg dose) with danicopan at steady state (200 mg three times daily for 4 days), the peak plasma concentration (Cmax) and systemic exposure (AUC) of rosuvastatin increased by 3.3-fold and 2.2-fold, respectively. An increase in rosuvastatin-related adverse effects may occur (e.g., myopathy and rhabdomyolysis).

MANAGEMENT: If concomitant use with danicopan is required, the manufacturer advises a dose reduction of rosuvastatin to a maximum recommended daily dosage of 10 mg. Closer monitoring for adverse effects such as myopathy and rhabdomyolysis may also be advised. Patients should be advised to promptly report unexplained muscle pain, tenderness, or weakness, particularly if accompanied by malaise or fever.